- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00352001
Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes
A Phase I/II Study of Revlimid (Lenalidomide) in Combination With Vidaza (Azacitidine) in Patients With Advanced Myelodysplastic Syndrome (MDS)
RATIONALE: Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Lenalidomide may also stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may also cause cancer cells to look more like normal cells, and to grow and spread more slowly. Giving lenalidomide together with azacitidine may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of lenalidomide and azacitidine in treating patients with advanced myelodysplastic syndromes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the maximum tolerated dose and dose-limiting toxicity of lenalidomide and azacitidine in patients with advanced myelodysplastic syndromes (MDS).
Secondary
- Review clinical outcomes, as defined by the International Working Group criteria, in patients treated with this regimen.
- Determine time to transformation to acute myeloid leukemia or death in patients treated with this regimen.
- Determine time to relapse after achieving complete or partial remission in patients treated with this regimen.
- Determine time to disease progression in patients treated with this regimen.
- Determine the effect of this regimen on hematologic status (including peripheral blood counts and the need for platelet and/or red blood cell transfusions) in these patients.
OUTLINE: This is an open-label, multicenter, dose-escalation study.
Patients receive oral lenalidomide once daily on days 1-14 or days 1-21 and azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses and/or increasing dosing frequencies of lenalidomide and azacitidine until the maximum tolerated dose (MTD) is determined or the sixth dose level is reached, whichever occurs first. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity during the first course of therapy.
After completion of study treatment, patients are followed annually.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-1781
- University of California at Los Angeles
-
-
Florida
-
Tampa, Florida, United States, 33612-9497
- H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of myelodysplastic syndromes (MDS) meeting one of the following criteria:
French-American-British histological classification criteria
Refractory anemia with excess blasts (RAEB), defined as 5-19% myeloblasts in the bone marrow
- Patients with 20% blasts are considered to have acute myeloid leukemia (per WHO classification system) and are therefore excluded in this study
- Chronic myelomonocytic leukemia (CMML), defined as 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood
WHO histological classification criteria
- RAEB-1, defined as 5-9% myeloblasts in the bone marrow
- RAEB-2, defined as 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood
- CMML-2, defined as 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood
- International Prognostic Scoring System (IPSS) score of intermediate 2 (1.5-2.0 points based on karyotype, cytopenias, and bone marrow blast percentage) or high (≥ 2.5 points), in the setting of ≥ 5% myeloblasts
- Considered ineligible for bone marrow transplantation as first-line therapy
PATIENT CHARACTERISTICS:
- Life expectancy ≥ 3 months
- ECOG performance status 0-2
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-method contraception for 4 weeks before, during, and for 4 weeks after completion of study treatment
- No serious medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the treating physician, would preclude study participation or preclude giving informed consent
- No preexisting neurotoxicity or neuropathy ≥ grade 2
- No rash or prior hypersensitivity or allergic reaction ≥ grade 3 to thalidomide
- Creatinine ≤ 2.0 mg/dL
- AST and ALT ≤ 2.0 times upper limit of normal
- Bilirubin ≤ 2 mg/dL
- Platelet count ≥ 50,000/mm^3
- Absolute neutrophil count ≥ 500/mm^3
- No other malignancy within the past 3 years except curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer
- No history of thromboembolic event or other condition requiring use of anticoagulation with warfarin or low molecular-weight heparin
- No known or suspected hypersensitivity to azacitidine or mannitol
PRIOR CONCURRENT THERAPY:
- More than 28 days since prior and no other concurrent investigational agents for MDS
- More than 28 days since prior approved therapy for MDS
- More than 14 days since prior growth factors
- More than 28 days since prior and no concurrent supraphysiologic doses (equivalent to > 10 mg/day of prednisone) of corticosteroids
- More than 12 months since prior radiotherapy, chemotherapy, or cytotoxic therapy for treatment of conditions other than MDS
- No prior lenalidomide or azacitidine
- No prior stem cell or bone marrow transplantation
- No concurrent androgens, epoetin alfa, or chemotherapy for MDS
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Lenalidomide and Azacitidine
|
Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12.
Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
Other Names:
Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PHASE I: Maximum Tolerated Dose of Azacitidine
Time Frame: After 1 courses (1 months)
|
Participants will be enrolled on the Phase I study portion in blocks of 3 to varying doses of Revlimid® (lenalidomide) and Vidaza® (azacitidine) (Table 1).
To determine the MTD, a standard "3+3" design will be used.
DLT will be assessed during the first cycle of therapy within each treatment group.
No Maximum dose was reach but the go-forward dose agreed upon by the investigators is reported here.
|
After 1 courses (1 months)
|
PHASE II: Determine the Number of Patients With Responses for Efficacy(Measured as Response Rate)
Time Frame: After 4 courses (4 months)
|
For the Phase II study portion, to determine the efficacy (measured as response rate) of the combination therapy as defined by the International Working Group (IWG) criteria (CR, complete remission; PR, partial remission; or HI, hematological improvement. Complete response (CR) is defined as: Disappearance of the chromosomal abnormality without appearance of new ones. Partial response (PR) is defined as: At least 50% reduction of the chromosomal abnormality. Hematologic Improvement (HI) is defined as: red blood cell increase of >=1.5g/dL, a platelet response of >=30X10^9/L or by at least 100% for values starting <20X10^9/L, or a neutrophil response of at least 100% and absolute increase of >0.5X10^9/L |
After 4 courses (4 months)
|
PHASE II: Determine the Number of Patients With Responses for Efficacy(Measured as Response Rate)
Time Frame: After 7 courses (months)
|
For the Phase II study portion, to determine the efficacy (measured as response rate) of the combination therapy as defined by the International Working Group (IWG) criteria (CR, complete remission; PR, partial remission; or HI, hematological improvement) Complete response (CR) is defined as: Disappearance of the chromosomal abnormality without appearance of new ones. Partial response (PR) is defined as: At least 50% reduction of the chromosomal abnormality. Hematologic Improvement (HI) is defined as: red blood cell increase of >=1.5g/dL, a platelet response of >=30X10^9/L or by at least 100% for values starting <20X10^9/L, or a neutrophil response of at least 100% and absolute increase of >0.5X10^9/L |
After 7 courses (months)
|
PHASE I: Maximum Tolerated Dose of Lenalidomide
Time Frame: After 1 courses (1 months)
|
Participants will be enrolled on the Phase I study portion in blocks of 3 to varying doses of Revlimid® (lenalidomide) and Vidaza® (azacitidine) (Table 1).
To determine the MTD, a standard "3+3" design will be used.
DLT will be assessed during the first cycle of therapy within each treatment group.
No Maximum dose was reach but the go-forward dose agreed upon by the investigators is reported here.
|
After 1 courses (1 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Transformation to Acute Myeloid Leukemia or Death
Time Frame: After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months
|
Time (in months) patients took to evolve to myeloid leukemia or death after achieving a complete response using the RECIST criteria
|
After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months
|
Time to Relapse After Achieving Complete Response
Time Frame: After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months
|
After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months
|
|
Number of Patients That Experience Grade 3 or 4 Treatment Related Non-hematologic Adverse Events
Time Frame: After 7 months
|
After 7 months
|
|
Overall Survival Among Patients With Complete Response
Time Frame: After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months
|
Time (in months) patients who achieved a complete response using the RECIST criteria were alive on study
|
After 7 months of treatment, until the date of first documented myeloid leukemia or death, whichever came first, assessed up to 55 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Precancerous Conditions
- Syndrome
- Myelodysplastic Syndromes
- Preleukemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Lenalidomide
- Azacitidine
Other Study ID Numbers
- CASE17Z05 (OTHER: Case Comprehensive Cancer Center)
- P30CA016042 (U.S. NIH Grant/Contract)
- UCLA-0511032-01
- UCLA-RDN-5405
- UCLA-05011032-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndromes
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
National Cancer Institute (NCI)CompletedPreviously Treated Myelodysplastic Syndromes | Secondary Myelodysplastic Syndromes | de Novo Myelodysplastic SyndromesUnited States
-
GCP-Service International West GmbHSaint-Louis Hospital, Paris, France; University of Florence; Medical University... and other collaboratorsNot yet recruitingLow Risk Myelodysplastic SyndromesSpain, Poland, Italy, Germany, France
-
Dana-Farber Cancer InstituteCompletedMyelodysplastic Syndromes (MDS)United States
-
I-Mab Biopharma Co. Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
-
Sumitomo Pharma America, Inc.TerminatedMyelodysplastic Syndromes (MDS)United States
Clinical Trials on azacitidine
-
Shandong Provincial HospitalUnknownMyelodysplastic Syndromes,Acute Myeloid LeukemiaChina
-
I-Mab Biopharma Co. Ltd.Recruiting
-
Eisai Inc.TerminatedMyelodysplastic SyndromesUnited States
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Celgene CorporationCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukaemia (AML)Australia
-
Navy General Hospital, BeijingRecruitingRefractory Classic Hodgkin Lymphoma | Relapsed Classic Hodgkin LymphomaChina
-
University of BirminghamRecruitingAcute Myeloid Leukemia | MyelodysplasiaUnited Kingdom
-
Nanexa ABUppsala UniversityCompletedMyelodysplastic Syndromes (MDS) | Acute Myeloid Leukemia (AML) | Chronic Myelomonocytic Leukemia (CMML)Sweden
-
Bristol-Myers SquibbRecruitingMyelodysplastic SyndromesUnited States, Canada, France, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Czechia, Korea, Republic of, Poland, Turkey
-
The First Affiliated Hospital of Soochow UniversityEnrolling by invitationMyelodysplastic/Myeloproliferative Neoplasms | AdultChina
-
CelgeneCompletedMyelodysplastic SyndromesUnited States